TW202118504A - A composition containing mulberry extract and production method thereof - Google Patents

Abstract

A composition containing mulberry extract comprises of at least a mulberry extract, a sweetener, and an additive; wherein the mulberry extract is obtained from an extraction of leaves or fruits by a solvent, e.g. water or alcohol, or obtained by a method using no solvent, e.g. supercritical fluid extraction or microwave-assisted extraction, or ultrasonic extraction; wherein the said mulberry extract comprises of such essential substance as phenolic or flavonoid compounds including anthocyanins, gallic acid, rutin or combination thereof; and it can be mixed with food, drink, supplementary food, or health products.

Description

Composition containing mulberry extract and production method thereof

Generally, the present invention relates to the field of compositions containing mulberry extracts (Morus alba or Morus spp.), which can be used as supplements and/or adaptogens, cognition Enhancer and reduce the risk of liver disease, peptic ulcer, metabolic syndrome, obesity and/or cardiovascular disease.

Morus, also known as mulberry, is a fast-growing medium and small plant. The leaves are arranged alternately, single leaves, and the leaf margins are often lobed and serrated. The taxonomy of Morus is complex, with more than 150 published species names, including Morus alba L., Morus australis Poir, Morus cathayana, Morus celtidifolia Kunth, Indian mulberry (Morus indica-L.), Morus insignis, Morus japonica Audib, Libosang (Morus liboensis SS), Milk mulberry (Morus macroura), African mulberry (Morus mesozygia Stapf), Monsang (Morus mongolica), black mulberry (Morus nigra L.), Chuan mulberry (Morus notabilis CK Schneid.), Red mulberry (Morus rubra L), Geelong mulberry (Morus serrata Roxb.), Split leaf mulberry (Morus trilobata), Long ear mulberry (Morus wittiorum Hand. -Mazz).

Mulberry is a compound fruit, about 2-3 cm long. Immature fruits are usually white, green or light yellow. In most species, the fruit turns pink when ripe, then red, then deep purple or black. However, the fruit of Ginkgo cultivars is white when mature. The color of mulberry is derived from water-soluble anthocyanins. Generally, the anthocyanin content depends on the climate and planting area, and is especially high in tropical regions. Ripe fruits are edible, usually in the form of fruit or juice. The leaves can also be eaten in the form of tea.

Morus plants or mulberry extracts are mostly used in the field of cosmetics. Only a few reports have found that Morus plants or mulberry extracts are used as nutritional or functional ingredients or foods, such as a composition including crude extracts of white mulberry fruit, which has neuroprotective activity (WO 2004/006946 A1) or a temperature Edible products for modulating and cognitive functions (US 2012/0087997 A1) indicate that the edible products include mulberry extract. The previous invention also includes the use of mulberry extract as an effective ingredient in food-use anorexics and air conditioners (US 2006/0222720 A1), and the use of mulberry extract as an ingredient in nutritional compositions and increase skeletal muscle The method of acid intake and retention to increase muscle mass and strength, increase exercise capacity and help recovery after exercise (US 2007/0196508 A1), and the use of mulberry extract and other medicinal plant extracts in those containing traditional Chinese medicine or its extracts Use in chewing gum, confectionery and other oral delivery vehicles (US 2010/0104518 A1).

The present invention aims to improve the health benefits of mulberry extract by combining with some additional compounds, wherein the combination provides increased efficacy of the compound in terms of cognitive enhancement effects and reduces liver disease, peptic ulcer, metabolic syndrome, obesity and / Or the risk of cardiovascular disease.

In view of this, our inventors devoted themselves to further research, and proceeded to develop and improve, hoping to develop a better invention to solve the above problems, and after continuous experimentation and modification, the present invention came out.

A composition comprising mulberry juice or concentrate or mulberry powder or extract, wherein the mulberry is obtained from mulberry leaves or mulberry fruits. The composition according to the present invention can be obtained from a process that does not use organic solvents, or can be obtained using water and alcohol extraction, wherein the extract includes phenols or flavonoids, including anthocyanins, gallic acid, Rutin or a combination thereof. The composition according to the present invention can be used as a tonic and/or adaptogen; a cognitive enhancer, and reduce the risk of liver disease, peptic ulcer, metabolic syndrome, obesity and/or cardiovascular disease. The use of the composition according to the present invention can be used in foods, beverages, food supplements or health products in any form.

Regarding the technical means of our inventors, several preferred embodiments are described in detail below in conjunction with the drawings, in order to provide a thorough understanding and approval of the present invention.

A composition comprising a mulberry extract, the composition comprising a mulberry extract at least includes a mulberry extract, a sweetener and an additive, wherein the composition each contains the following amounts:

Mulberry extract 1-60% w/w

Sweetener 0.9-60% w/w

Additives make the total amount 100% w/w

Wherein, the additives may be selected from any one or more of maltodextrin, fillers, stabilizers, anti-caking agents, acidulants, gelling agents, artificial flavors, food colorings, water and milk.

One or more embodiments of the present invention will be described in detail with reference to a sample composition containing a mulberry extract. However, the sample composition containing a mulberry extract according to the present invention is not intended to limit the scope of one or more embodiments of the present invention. The following examples are provided to illustrate certain embodiments of the invention. Those with ordinary knowledge in the technical field to which the present invention belongs will understand that the present invention is not limited by the specific implementation of the following examples:

1) A composition containing mulberry extract in the form of a capsule comprising

a. Mulberry extract 1-60% w/w

b. Maltodextrin 19-60% w/w

c. The stabilizer can be selected from gum arabic or polydextrose 2-20% w/w

The mulberry extract-containing composition in the form of a capsule further includes a filler or an anti-caking agent, the filler may be selected from 0.01-37% w/w tapioca flour or lactose, and the anti-caking agent may be selected from 0.01- 37% w/w magnesium stearate or silicon dioxide.

2) A composition containing mulberry extract in the form of an instant powder beverage comprising

a. Mulberry extract 1-60% w/w

b. Filler 36-98% w/w

c. Sweetener 0.9-3% w/w

d. Acidifier 0.1-1% w/w

3) A composition containing mulberry extract in the form of a gel beverage comprising

a. Mulberry extract 1-60% w/w

b. Water 38-84% w/w

c. Sweetener 0.9-12% w/w

d. Gelling agent 1-2% w/w

e. Acidifier 0.1-1% w/w

4) A composition containing mulberry extract and milk in the form of a powdered milk beverage includes

a. Mulberry extract 2-50% w/w

b. Milk 47-97% w/w

c. Sweetener 1-3% w/w

5) A composition containing mulberry extract and milk in the form of a milk beverage includes

a. Mulberry extract 1-50% w/w

b. Milk 20-87% w/w

c. Sweetener 1-6% w/w

d. Maltodextrin 7-10% w/w

e. Carrageenan 1-10% w/w

Add artificial flavor and/or food coloring.

The composition comprising a mulberry extract according to the present invention, wherein the mulberry extract is passed through a solvent (preferably an organic solvent, the solvent is selected from essential substances of mulberry fruit or leaves or a combination thereof, and the organic solvent may be selected from water or Alcohol or its combination) is obtained from mulberry fruit or mulberry leaf or its combination of essential substances, or obtained without the use of solvents, for example, the use of supercritical fluid extraction of the substance under the conditions of temperature and pressure higher than the critical point, or microwave-assisted extraction Or ultrasonic extraction.

One or more embodiments of the present invention will be described in detail with reference to a sample composition containing a mulberry extract. However, the sample composition containing a mulberry extract according to the present invention is not intended to limit the scope of one or more embodiments of the present invention. The following examples are provided to illustrate certain embodiments of the invention. Those skilled in the art will understand that the present invention is not limited by the specific implementation of the following examples:

1) Dry

Bake the mulberries at a temperature of 50-60 degrees Celsius for 48-72 hours or until the moisture is below 10%, and then grind them into powder.

2) Extraction of mulberry extract

Dry mulberry powder is extracted with a solvent (ie, water or alcohol). The mulberry powder is soaked in the solvent for 1-3 days, and then repeated stirring for 2-3 rounds every 6 hours. Then, the filtered water is filtered and removed, dried in a spray dryer or freeze dryer, and then the extract is mixed with several products.

The present invention discloses a composition comprising mulberry juice or concentrate or mulberry powder or extract, wherein the mulberry is obtained from mulberry leaves or mulberry fruits. The mulberry leaf or mulberry fruit according to the present invention can be derived from white mulberry (Morus alba L.), chicken mulberry (Morus australis Poir), Chinese mulberry (Morus cathayana), Pusang (Morus celtidifolia Kunth), Indian mulberry (Morus indica- L.), Morus insignis, Morus japonica Audib, Libosang (Morus liboensis SS), Milk Mulberry (Morus macroura), African Mulberry (Morus mesozygia Stapf), Monsang (Morus mongolica), Black Mulberry (Morus nigra L.) , Morus notabilis CK Schneid., Morus rubra L, Morus serrata Roxb., Morus trilobata, Morus wittiorum Hand.-Mazz.

As shown in [Table 1], the mulberry extract according to the present invention includes phenolic or flavonoids, including anthocyanins, gallic acid, and rutin.

[ Table 1 ] Phenolic components of mulberry parameter mulberry Total phenols (µg GAE/g extract) 0.1 -1,000 Total flavonoids (µg quercetin/g extract) 0.1 -1,000 Anthocyanins (µg Cyn-3-glu/g extract) 1-1,000 Gallic acid (µg GAE/g extract) 10-900

The phenolic compound and flavonoid content in the mulberry extract according to the present invention ranges from 0.1 to 1000 µg GAE/g extract, and the anthocyanin content ranges from 100 to 1000 µg/g extract.

The composition comprising mulberry extract according to the present invention can be used as a tonic and/or adaptogen; a cognitive enhancer, and reduce the risk of liver disease, peptic ulcer, metabolic syndrome, obesity, and/or cardiovascular disease. The adaptogenic properties of the composition containing the mulberry extract of the present invention are caused by acting on multiple target organs, and these effects include, but are not limited to, changes in sympathetic effects and oxidative stress balance, such as [Table 2] And [Table 3].

[ Table 2 ] The effects of different doses of MME on the activities of acetylcholinesterase (AChE) and monoamine oxidase (MAO) in the hippocampus Treatment group MAO activity (µmol/ml) ND+ solvent 0.33 ± 0.35 HCHF+ solvent 5.75 ± 0.57 ^aaa OVX+HCHF+ solvent 4.53 ± 0.36 ^aaa OVX+HCHF+Isoflavone 15 mg/kg BW 3.76 ± 0.66 OVX+HCHF+MME 10 mg/kg BW 0.06 ± 0.44*** OVX+HCHF+MME 50 mg/kg BW 2.10 ± 0.31*** OVX+HCHF+MME 250 mg/kg BW 3.79 ± 0.44

Data are expressed as mean ± SEM (n=6/group). ^aaa p value <.001; compared with normal rats receiving normal feed, ^bbb p value <.001; compared with normal rats receiving HCHF feed and vehicle, *, **, ***p values were respectively < .05, .01, .001; compared to OVX rats that received HCHF and vehicle. ND, normal feed; HCHF, high carbohydrate and high fat feed; OVX-HCHF, ovariectomized plus high carbohydrate and high fat feed.

[ Table 3 ] The effect of different doses of MME on the activities of acetylcholinesterase (AChE) and monoamine oxidase (MAO) in the prefrontal cortex Treatment group MAO activity (µmol/ml) ND+ solvent 0.66 ± 0.64 HCHF+ solvent 7.91 ± 0.49 ^aaa OVX+HCHF+ solvent 6.20 ± 1.30 ^aaa OVX+HCHF+Isoflavone 15 mg/kg BW 3.70 ± 0.75* OVX+HCHF+MME 10 mg/kg BW 0.32 ± 0.22*** OVX+HCHF+MME 50 mg/kg BW 2.96 ± 0.75** OVX+HCHF+MME 250 mg/kg BW 4.85 ± 0.40

Data are expressed as mean ± SEM (n=6/group). ^{aa, aaa} p values <.01, .001; compared with normal rats receiving normal feed and vehicle, *, **, *** p values <.05, .01 and .001; compared with receiving HCHF Compared with vehicle OVX rats. ND: normal feed, HCHF: high carbohydrate high fat feed; OVX-HCHF: ovariectomized plus high carbohydrate high fat feed, MME10, 50, and 250: microencapsulated at doses of 10, 50, and 250 mg/kg BW, respectively Mulberry extract.

It is known that when pro-inflammatory cytokines (ie NF-kB, TNF-α) are inhibited or the function and epigenetic mechanism of peroxisome proliferation activated receptors are changed, the risk of liver disease can be reduced. Therefore, as shown in [Table 4-6] and Fig. 1, the composition comprising mulberry extract according to the present invention can be used to prevent or reduce the risk of liver disease due to its biological activity.

[ Table 4 ] Serum biochemical parameters Treatment group Estradiol (pg/mL) ALT (Unit/L) AST (unit/L) ND+ solvent 25.39 ± 14.61 10.75 ± 0.75 120.50 ± 6.74 HCHF+ solvent 26.43 ± 9.46 16.67 ± 2.25 ^a 155.20 ± 10.10 ^a OVX+HCHF+ solvent 5.00 ± 0.00 ^{a, bb} 19.00 ± 3.19 ^aa 158.00 ± 22.68 ^a OVX+HCHF+Isoflavone 15 mg/kg BW 8.15 ± 1.95 12.67 ± 1.33* 133.00 ± 4.62 OVX+HCHF+L-carnitine 250 mg/kg BW 7.69 ± 1.81 11.50 ± 0.65** 109.00 ± 6.42** OVX+HCHF+MME 10 mg/kg BW 5.00 ± 0.00 11.75 ± 1.11** 122.67 ± 10.17* OVX+HCHF+MME 50 mg/kg BW 10.28 ± 5.28 10.75 ± 0.75** 110.75 ± 10.78** OVX+HCHF+MME 250 mg/kg BW 11.24 ± 5.97 9.80 ± 1.07*** 97.40 ± 6.19***

Data are expressed as mean ± SEM (n=6/group). ^{a, aa} p values <.05, .01; compared with control rats receiving normal feed and vehicle, ^bb p value <.01; compared with normal rats receiving HCHF feed and vehicle, *, ** , *** p values <.05, .01, .001, respectively; compared with OVX rats that received HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, OVX+HCHF: ovariectomized and receiving high carbohydrate and high fat feed, MME10, 50 and 250: microcapsules with doses of 10, 50 and 250 mg/kg BW, respectively Mulberry fruit extract.

[ Table 5 ] The effect of different doses of MME on the oxidative stress state of the liver Treatment group MDA level ( ng/mg. protein) SOD activity ( unit/mg. protein) CAT activity ( unit/mg. protein) GSH-Px activity ( unit/mg. protein) ND+ solvent 0.51 ± 0.10 5.37 ± 0.41 21.82 ± 0.25 0.199 ± 0.007 HCHF+ solvent 0.96 ± 0.08 ^aaa 2.94 ± 0.19 19.92 ± 0.80 0.153 ± 0.014 ^a OVX+HCHF+ solvent 0.85 ± 0.06 ^a 1.51 ± 1.39 ^a 18.20 ± 0.36 ^a 0.118 ± 0.003 ^aaa OVX+HCHF+ Isoflavone 15 mg/kg BW 0.37 ± 0.10*** 7.07 ± 1.46** 22.11 ± 0.86* 0.122 ± 0.010 OVX+HCHF+ L-Carnitine 250 mg/kg BW 0.60 ± 0.07* 8.92 ± 1.33*** 24.17 ± 1.67** 0.185 ± 0.024** OVX + HCHF + MME 10 mg/kg BW 0.36 ± 0.08*** 8.28 ± 1.09*** 22.43 ± 1.69* 0.147 ± 0.005 OVX + HCHF + MME 50 mg/kg BW 0.41 ± 0.05*** 5.05 ± 1.09* 23.25 ± 0.94** 0.161 ± 0.015* OVX + HCHF + MME 250 mg/kg BW 0.46 ± 0.08** 4.98 ± 0.38* 22.75 ± 0.46** 0.159 ± 0.016*

Data are expressed as mean ± SEM (n=6/group). ^{a, aaa} p values <.05, .001; compared with control rats receiving normal feed and vehicle, *, **, *** p values <.05, .01 and .001; compared with receiving HCHF Compared with vehicle OVX rats. ND: normal feed, HCHF: high carbohydrate and high fat feed, OVX+HCHF: ovariectomized and receiving high carbohydrate and high fat feed, MME10, 50 and 250: microcapsules with doses of 10, 50 and 250 mg/kg BW, respectively Mulberry fruit extract.

[ Table 6 ] The effect of different doses of MME on liver histopathology Treatment group Steatosis score Inflammation score Kupffer cell number Nuclear pyknosis score ND+ solvent 0.07 ± 0.07 0.87 ± 0.17 70.93 ± 4.36 0.60 ± 0.13 HCHF+ solvent 1.38 ± 0.31 ^aaa 2.62 ± 0.15 ^aaa 108.57 ± 3.65 ^aaa 1.33 ± 0.19 ^a OVX+HCHF+ solvent 2.13 ± 0.31 ^{aaa, b} 1.73 ± 0.15 ^{aa, bb} 93.47 ± 5.40 ^{aaa, bb} 3.80 ± 0.13 ^{aaa, bbb} OVX+HCHF+ Isoflavone 15 mg/kg BW 1.13 ± 0.29* 0.93 ± 0.22** 73.73 ± 3.05*** 0.60 ± 0.22*** OVX+HCHF+ L-Carnitine 250 mg/kg BW 0.67 ± 0.11*** 0.93 ± 0.32** 81.67 ± 2.82* 1.00 ± 0.24*** OVX + HCHF + MME 10 mg/kg BW 1.00 ± 0.29** 0.73 ± 0.06*** 68.56 ± 1.54*** 1.23 ± 0.21*** OVX + HCHF + MME 50 mg/kg BW 1.11 ± 0.21** 0.72 ± 0.23*** 70.05 ± 1.20*** 0.94 ± 0.16*** OVX + HCHF + MME 250 mg/kg BW 0.50 ± 0.17*** 0.95 ± 0.13** 69.56 ± 2.21*** 1.33 ± 0.29***

Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values <.05, .01, .001; compared with control rats that received normal feed and vehicle, ^{b, bb, bbb} p values were <.05, .01, .001; and Compared with normal rats that received HCHF feed and vehicle, the p values of *, **, *** were <.05, .01, and .001, respectively; compared with OVX rats that received HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, OVX+HCHF: ovariectomized and receiving high carbohydrate and high fat feed, MME10, 50 and 250: microcapsules with doses of 10, 50 and 250 mg/kg BW, respectively Mulberry fruit extract.

As shown in Figures 4 and 5 and [Table 7], the composition according to the present invention has potential use for reducing the risk of peptic ulcer by reducing the oxidative stress of the mulberry extract.

[ Table 7 ] The effect of mulberry fruit on the level of malondialdehyde (MDA) and oxidative stress in the hippocampus of rats exposed to cold fixation stress Treatment group MDA concentration (nmol/mg protein) Superoxide dismutase (unit/mg protein) Catalase (unit/mg protein) Glutathione peroxidase (units/mg protein) Hippocampus Hippocampus Hippocampus Hippocampus Control (blank) 0.94 ± 0.02 0.61 ± 0.02 0.03 ± 0.02 0.72 ± 0.04 ^* Solvent + stress 0.15 ± 0.04 0.56 ± 0.05 0.18 ± 0.02 0.55 ± 0.03 ^a MF 2 mg/kg+stress 0.07 ± 0.02 ^* 0.65 ± 0.01 0.23 ± 0.04 0.69 ± 0.03 ^* MF 10 mg/kg+stress 0.06 ± 0.01 ^* 0.78 ± 0.04 ^a* 0.31 ± 0.07 ^* 0.76 ± 0.07 ^** MF 50 mg/kg+stress 0.10 ± 0.02 0.67 ± 0.06 0.28 ± 0.03 0.70 ± 0.06 ^* T 15 mg/kg+stress 0.07 ± 0.01 ^* 0.79 ± 0.08 ^a* 0.33 ± 0.07 ^* 0.73 ± 0.04 ^**

MF: Mulberry T: Tianeptine

The composition according to the present invention is used to reduce fat cells, improve metabolic status, reduce obesity index, reduce oxidative stress and inhibit pro-inflammatory cytokines (ie NF-kB, TNF-α) and/or change peroxidation through mulberry extract The potential use of proteasome proliferation to activate receptor function and inhibit pancreatic lipase to reduce the risk of metabolic syndrome, as shown in [Table 8-9].

[ Table 8 ] The effect of microencapsulated mulberry extract (MME) on metabolic parameters parameter ND+ solvent HCHF+ solvent OVX+HCHF+ solvent OVX + HCHF + Isoflavone 15 OVX + HCHF + L-car250 OVX + HCHF + MME10 OVX + HCHF + MME50 OVX + HCHF + MME250 Weight gain (%) 3.03±1.43 9.32±1.30 ^a 8.96±0.80 ^a 1.53±2.78** 1.12±2.00** 3.73±2.10* 6.34±0.57 2.15±0.97* TC (mg/dL) 4 weeks 138.92±5.73 140.02±4.21 240.93±23.39 ^{aaa, bbb} 139.03±6.65*** 167.77±6.48*** 191.29±9.52** 154.15±6.89*** 174.86±6.87*** 8 weeks 134.64±5.95 154.00±4.33 193.58±34.79 ^aa,b 132.50±9.63*** 146.68±1.88* 146.12±1.51** 152.65±8.30* 152.58±3.96* Triglycerides (mg/dL) 4 weeks 133.64±1.72 132.43±4.32 165.49±2.10 ^{aaa, bbb} 144.44±6.23** 118.18±2.58*** 152.15± 4.75* 145.58±2.76** 142.64±1.16** 8 weeks 131.88±4.59 147.98±10.53 167.59±8.22 ^aaa,b 142.35±3.59** 127.56±4.69*** 146.99±6.80* 145.03±1.87* 141.25±1.85** HDL-C (mg/dL) 4 weeks 43.45±3.42 12.95±5.17 ^aaa 8.11±1.46 ^aaa 18.62±0.85 20.84±2.13* 28.35±2.22** 28.78±5.07** 31.42±5.98*** 8 weeks 54.37±2.63 9.30±2.44 ^aaa 7.22±0.88 ^aaa 11.19±2.62 32.41±8.48*** 28.27±4.09*** 25.03±4.33** 23.70±5.12** LDL-C (mg/dL) 4 weeks 8.29±0.36 16.32±1.97 ^a 20.20±1.84 ^aa 6.47±2.27*** 11.61±5.06* 5.91±1.97*** 8.04±0.68** 11.68±2.53* 8 weeks 12.85±1.37 17.32±3.22 18.38±0.34 ^a 8.65±1.50*** 7.70±2.72*** 8.73±1.04*** 9.05±0.44*** 4.85±1.20*** FBG (mg/dL) 4 weeks 97.00±5.73 108.25±4.05 115.33±4.63 ^a 125.50±11.29 104.50±3.95 98.25±2.43* 87.80±1.98** 95.60±1.81* 8 weeks 94.80±5.36 117.50±4.29 ^aaa 109.33±1.86 ^a 103.80±3.20 107.25±4.80 101.67±2.73 95.67±0.67* 97.00±2.12* Plasma glucose AUC (mg h/dL) 4 weeks 287.13±25.47 369.30±30.77 ^aa 355.75±20.45 ^a 355.30±14.34 400.19±16.76 298.88±12.34 290.45±19.06* 311.70±12.56 8 weeks 266.90±10.34 346.29±12.14 ^aa 421.75±29.80 ^aaa,bb 350.50±13.04** 360.25±14.13* 344.94±15.32** 346.15±22.17** 364.94±21.94*

Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values <.05, .01, .001; compared with control rats that received normal feed and vehicle, ^{b, bb, bbb} p values were <.05, .01, .001; and Compared with normal rats that received HCHF feed and vehicle, the p values of *, **, *** were <.05, .01, and .001, respectively; compared with OVX rats that received HCHF and vehicle.

[ Table 9 ] The effect of different doses of MME on oxidative stress markers in adipose tissue Treatment group MDA level (ng/mg. protein) SOD activity (unit/mg. protein) CAT activity (unit/mg. protein) GSH-Px activity (unit/mg. protein) ND+ solvent 0.52 ± 0.13 13.91 ± 2.21 375.89±87.06 1.39 ± 0.36 HCHF+ solvent 1.10 ± 0.09 ^aa 7.95 ± 0.84 ^aaa 269.48 ± 27.31 ^a 1.01 ± 0.10 ^a OVX+HCHF+ solvent 1.64 ± 0.09 ^{aaa, bb} 7.31 ± 1.28 ^aaa 211.21 ± 3.89 ^aa 0.79 ± 0.06 ^aaa OVX+HCHF+Isoflavone 15 mg/kg BW 1.26 ± 0.06* 13.05 ± 0.87*** 268.93 ± 24.81 1.22 ± 0.13** OVX+HCHF+ L-Carnitine 250 mg/kg BW 0.76 ± 0.17*** 10.96 ± 0.36* 251.36 ± 9.15 1.01 ± 0.03 OVX + HCHF + MME 10 mg/kg BW 0.78 ± 0.06*** 12.61 ± 0.88*** 335.54±18.96** 1.22 ± 0.06* OVX + HCHF + MME 50 mg/kg BW 1.00 ± 0.14*** 9.96 ± 0.51* 308.55 ± 16.36* 1.20 ± 0.07* OVX + HCHF + MME 250 mg/kg BW 0.96 ± 0.13*** 10.89 ± 0.63** 315.25 ± 19.00* 1.19 ± 0.03*

Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values <.05, .01, .001; compared with control rats receiving normal feed and vehicle, ^bb p value <.01; compared with normal rats receiving HCHF feed and vehicle , *, **, *** p values <.05, .01, .001, respectively; compared with OVX rats that received HCHF and vehicle.

The composition according to the present invention is used for the potential use of mulberry extract to reduce fat cells, improve the metabolic status and reduce the obesity index to reduce the risk of obesity, as shown in Figs. 8-13.

The potential use of the composition according to the present invention for reducing the risk of cardiovascular disease by inhibiting angiotensin-converting enzyme and/or improving the atherogenic index by mulberry extract is shown in [Table 10].

[ Table 10 ] The effect of microencapsulated mulberry extract (MME) on angiotensin converting enzyme (ACE) and atherogenic index (AI) parameter ND+ solvent HCHF+ solvent OVX+HCHF+ solvent OVX + HCHF + Isoflavone 15 OVX + HCHF + L-car250 OVX + HCHF + MME10 OVX + HCHF + MME50 OVX + HCHF + MME250 Atherosclerosis index 4 weeks 3.26±0.26 20.92±6.57 ^aa 20.63±4.28 ^aa 22.11±7.45 8.40±0.69* 7.28±0.97* 5.72±1.14* 6.51±0.85* 8 weeks 2.61±0.13 24.05±4.67 ^aaa 23.36±3.15 ^aaa 15.08±3.81* 6.02±1.28*** 6.20±0.93*** 5.91±0.80*** 7.22±1.83*** ACE (unit/mg. protein) 0.019±0.001 0.028±0.001 ^aaa 0.028±0.002 ^aaa 0.020±0.002** 0.020±0.001** 0.022±0.002* 0.020±0.001*** 0.020±0.001***

Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values <.05, .01, .001; compared with control rats that received normal feed and vehicle, ^{b, bb, bbb} p values were <.05, .01, .001; and Compared with normal rats that received HCHF feed and vehicle, the p values of *, **, *** were <.05, .01, and .001, respectively; compared with OVX rats that received HCHF and vehicle.

The composition comprising mulberry extract according to the present invention can be used to enhance cholinergic function and/or reduce oxidative stress and/or neurogenesis and/or enhance signal transduction via mitogen-activated protein kinase (MAPK) Improve cognitive function, as shown in [Table 11].

[ Table 11 ] The effect of different doses of MME on hippocampal oxidative stress markers Treatment group MDA level ( ng/mg. protein) SOD activity ( unit/mg. protein) CAT activity ( unit/mg. protein) GSH-Px activity ( unit/mg. protein) ND+ solvent 4.38 ± 1.41 59.28 ± 6.40 780.07 ± 104.63 10.86 ± 1.04 HCHF+ solvent 14.27 ± 2.36 ^aaa 47.39 ± 5.86 ^a 517.12 ± 53.99 ^aa 7.29 ± 0.96 ^aa OVX+HCHF+ solvent 11.85 ± 0.85 ^aa 14.28 ± 0.82 ^{aaa, bbb} 201.80 ± 12.04 ^{aaa, bbb} 3.64 ± 0.52 ^{aaa, bbb} OVX+HCHF+Isoflavone 15 mg/kg BW 7.05 ± 0.69* 30.74 ± 2.71* 411.66 ± 37.81* 4.72 ± 0.42 OVX + HCHF + MME 10 mg/kg BW 6.51 ± 0.98* 38.15 ± 2.53*** 446.31 ± 51.80** 6.94 ± 0.69** OVX + HCHF + MME 50 mg/kg BW 4.93 ± 0.61** 30.07 ± 0.56* 427.58 ± 15.64** 6.06 ± 0.36* OVX + HCHF + MME 250 mg/kg BW 5.06 ± 0.69** 31.40 ± 1.64** 464.92 ± 38.16** 7.27 ± 0.43**

Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values <0.05, 0.01 and .001; compared with control rats receiving normal feed and vehicle, ^bbb p value <.001; compared with normal rats receiving HCHF feed and vehicle, * , **, *** p values <.05, .01 and .001, respectively; compared with OVX rats that received HCHF and vehicle.

The composition according to the present invention can be used in foods, food products, beverages, milk or food supplements or health products, wherein the food, beverages, milk or food supplements or health products can be tablets, capsules, effervescent Granules or in the form of tablets, granules, powders, gels, jellies, gums, candies, sprays, films, patches, creams, ointments, lotions or the like.

In summary, the technical means disclosed in the present invention can effectively solve the conventional problems and achieve the expected purpose and effect. It has not been seen in the publications, has not been used publicly, and has long-term progress before the application. The patent law claims that the invention is correct. Yan filed an application in accordance with the law and prayed that Jun Shanghui would give a detailed examination and grant a patent for invention.

However, the above are only a few preferred embodiments of the present invention, and should not be used to limit the scope of implementation of the present invention, that is, all equivalent changes and modifications made in accordance with the scope of the patent application of the present invention and the content of the description of the invention are all It should still fall within the scope of the patent for this invention.

〔this invention〕 no

[Figure 1] shows the results of an optical microscope of liver tissue sections stained with hematoxylin and eosin (H&E) at 20 times magnification. A: Normal feed (ND) + solvent, B: HCHF + solvent, C: OVX-HCHF feed + solvent, D: OVX-HCHF feed + isoflavone 15 mg/kg BW, E: OVX-HCHF feed + L-carnitine 250 mg/kg BW, F: OVX-HCHF feed+MME 10 mg/kg BW, G: OVX-HCHF feed+MME 50 mg/kg BW and H: OVX-HCHF feed+MME 250 mg/kg BW. ND: normal feed, HCHF: high carbohydrate high fat feed, Veh: vehicle, OVX-HCHF: ovariectomized high carbohydrate high fat feed, Iso: isoflavones at a dose of 15 mg/kg BW, MME10, 50 and 250 : Microencapsulated mulberry extract at doses of 10, 50, and 250 mg/kg BW. [Figure 2] shows the effect of Western blot detection (a) and quantitative analysis (b) of different doses of MME on the relative density of NF-kB and TNF-α in liver tissue. The levels of β-actin were normalized to the levels of NF-kB and TNF-α. Calculate the relative density of NF-kB and TNF-α levels relative to control normal diet plus vehicle rats. Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaa} p values were <.05, 0.01 and .001; compared with control rats that received normal feed and vehicle, *, ** p values were <.05, 01; compared with those who received HCHF and vehicle Compared to OVX rats. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: solvent, OVX-HCHF: ovariectomized and high carbohydrate high fat feed, Iso: isoflavone dose is 15 mg/kg BW, MME10, 50 and 250: Microencapsulated mulberry extracts at doses of 10, 50, and 250 mg/kg BW. [Figure 3] shows the effect of different doses of MME on the relative density of DNMT-1 and PPAR-γ in liver tissues by Western blot detection (a) and quantitative analysis (b). The levels of β-actin were normalized to the levels of DNMT-1 and PPAR-γ. Calculate the relative density of their DNMT-1 and PPAR-γ levels relative to the control normal diet plus vehicle rats. Data are expressed as mean ± SEM (n=6/group). ^{a, aaa} p values <.05, .001; compared with control rats receiving normal feed and vehicle, ^b p value <.05; compared with normal rats receiving HCHF feed and vehicle, *, ** *p values <.05, .001, respectively; compared with OVX rats that received HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: vehicle, OVX-HCHF, ovariectomized and receiving high carbohydrate and high fat feed, Iso: isoflavones at a ^{dose of 15 mg.kg -1 BW, L-} car: L-carnitine at a dose of 250 mg.kg ^-1 BW, MME10, 50 and 250: microencapsulated mulberry extract at a ^{dose of 10, 50 and 250 mg.kg -1 BW, respectively.} [Figure 4] shows the effect of mulberry on gastritis in rats that received oral treatment with vehicle or ranitidine 50 mg/kg BW or mulberry 2, 10, 50 mg/kg BW. Data are expressed as mean ± SEM (n=5/group). ^aaa P value <0.001, compared with the control treatment group, ^* P value <0.05, compared with the vehicle treatment group, ^** P value <0.01, compared with the vehicle treatment group, ^*** P value <0.001, compared with the vehicle treatment group Compared with the treatment group. [Figure 5] shows the effect of mulberry fruit on gastritis in rats that received oral treatment with vehicle or ranitidine or mulberry powder. (A: control (blank), B: vehicle + stress, C: mulberry 2 mg/kg BW+stress, D: mulberry 10 mg/kg BW+stress, E: mulberry 50 mg/kg BW+stress , F: Ranitidine 50 mg/kg BW+stress). [Figure 6] shows the effects of (a) and quantitative analysis (b) of different doses of MME on the relative density of NF-kB and TNF-α in adipose tissue by Western blotting. The levels of β-actin were normalized to the levels of NF-kB and TNF-α. Calculate the relative density of NF-kB and TNF-α levels relative to control normal diet plus vehicle rats. Data are expressed as mean ± SEM (n=6/group). ^{a, aa, aaap} values <.05, .01, .001; compared with control rats receiving normal feed and vehicle, ^b p value <.05; compared with normal rats receiving HCHF feed and vehicle, *, *** p values <.05, .001, respectively; compared with OVX rats that received HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: vehicle, OVX-HCHF: ovariectomized plus high carbohydrate high fat feed, Iso: 15 mg/kg BW isoflavones, L-car: dose L-carnitine at 250 mg/kg BW, MME10, 50, and 250: Microencapsulated mulberry extract at doses of 10, 50, and 250 mg/kg BW, respectively. [Figure 7] shows the effect of different doses of MME on the relative density of PPAR-γ in adipose tissue by Western blot detection (a) and quantitative analysis (b). The level of β-actin was normalized to the level of PPAR-γ. The relative density of their PPAR-γ levels was calculated relative to the control normal diet plus vehicle rats. Data are expressed as mean ± SEM (n=6/group). ^a p value <.05; compared with the control rats receiving normal feed and vehicle, **, *** p values <.01, .001, respectively; compared with OVX rats receiving HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: vehicle, OVX-HCHF: ovariectomized plus high carbohydrate high fat feed, Iso: 15 mg/kg BW isoflavones, L-car: dose L-carnitine at 250 mg/kg BW, MME10, 50, and 250: Microencapsulated mulberry extract at doses of 10, 50, and 250 mg/kg BW, respectively. [Figure 8] shows the results of an optical microscope of white adipose tissue stained with hematoxylin and eosin (H&E) at 40 times magnification. A: Normal feed (ND) + solvent, B: HCHF + solvent, C: OVX-HCHF feed + solvent, D: OVX-HCHF feed + isoflavone 15 mg/kg BW, E: OVX-HCHF feed + L-carnitine 250 mg/kg BW, F: OVX-HCHF feed+MME 10 mg/kg BW, G: OVX-HCHF feed+MME 50 mg/kg BW and H: OVX-HCHF feed+MME 250 mg/kg BW. [Figure 9] shows the results of an optical microscope of white adipose tissue in the mesentery area stained with hematoxylin and eosin (H&E) under 40x magnification. A: Normal feed (ND) + solvent, B: HCHF + solvent, C: OVX-HCHF feed + solvent, D: OVX-HCHF feed + isoflavone 15 mg/kg BW, E: OVX-HCHF feed + L-carnitine 250 mg/kg BW, F: OVX-HCHF feed+MME 10 mg/kg BW, G: OVX-HCHF feed+MME 50 mg/kg BW and H: OVX-HCHF feed+MME 250 mg/kg BW. [Fig. 10] shows the result of an optical microscope of white adipose tissue in the retroperitoneal area stained with hematoxylin and eosin (H&E) under 40x magnification. A: Normal feed (ND) + solvent, B: HCHF + solvent, C: OVX-HCHF feed + solvent, D: OVX-HCHF feed + isoflavone 15 mg/kg BW, E: OVX-HCHF feed + L-carnitine 250 mg/kg BW, F: OVX-HCHF feed+MME 10 mg/kg BW, G: OVX-HCHF feed+MME 50 mg/kg BW and H: OVX-HCHF feed+MME 250 mg/kg BW. [Fig. 11] shows the result of an optical microscope of white adipose tissue in the subcutaneous area stained with hematoxylin and eosin (H&E) under 40x magnification. A: Normal feed (ND) + solvent, B: HCHF + solvent, C: OVX-HCHF feed + solvent, D: OVX-HCHF feed + isoflavone 15 mg/kg BW, E: OVX-HCHF feed + L-carnitine 250 mg/kg BW, F: OVX-HCHF feed+MME 10 mg/kg BW, G: OVX-HCHF feed+MME 50 mg/kg BW and H: OVX-HCHF feed+MME 250 mg/kg BW. [Figure 12] shows the effect of different doses of MME on the density of adipocytes in all areas. Data are expressed as mean ± SEM (n=6/group). ^{aa, aaap} values <.01, .001; compared with control rats receiving normal feed and vehicle, ^{bb, bbb} p values were <.01, .001; compared with normal rats receiving HCHF feed and vehicle , *, **, *** p values <.05, .01, .001, respectively; compared with OVX rats that received HCHF and vehicle. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: vehicle, OVX-HCHF: ovariectomized plus high carbohydrate high fat feed, Iso: 15 mg/kg BW isoflavones, L-car: dose L-carnitine at 250 mg/kg BW, MME10, 50, and 250: Microencapsulated mulberry extract at doses of 10, 50, and 250 mg/kg BW, respectively. [Figure 13] shows the effect of different doses of MME on the size of adipocytes in all regions. Data are expressed as mean ± SEM (n=6/group). ^aaa p value <.001; compared with control rats receiving normal feed and vehicle, *, **, *** p values .05, .01, .001; compared with OVX rats receiving HCHF and vehicle ratio. ND: normal feed, HCHF: high carbohydrate and high fat feed, Veh: vehicle, OVX-HCHF: ovariectomized plus high carbohydrate high fat feed, Iso: 15 mg/kg BW isoflavones, L-car: dose L-carnitine at 250 mg/kg BW, MME10, 50, and 250: Microencapsulated mulberry extract at doses of 10, 50, and 250 mg/kg BW, respectively.

Claims (17)

A composition comprising a mulberry extract. The composition comprising a mulberry extract at least includes a mulberry extract, a sweetener and an additive. The composition comprising a mulberry extract according to claim 1, wherein each of the compositions comprises the following amounts: Mulberry extract 1-60% w/w Sweetener 0.9-60% w/w Additives make the total amount 100% w/w. The composition comprising a mulberry extract according to claim 1, wherein the additives may be selected from maltodextrin, fillers, stabilizers, anti-caking agents, acidulants, gelling agents, artificial flavors, food Any one or more of pigments, water and milk. A composition comprising a mulberry extract, wherein the mulberry is obtained from mulberry leaves or mulberry fruits. The composition comprising a mulberry extract according to claim 1, wherein the mulberry selection may be selected from mulberry or Morus or a combination thereof. The composition comprising a mulberry extract according to claim 1, wherein the mulberry extract is obtained by a method using an organic solvent or a method without using an organic solvent. The composition comprising a mulberry extract according to claim 1 or 6, wherein the mulberry extract is obtained by a method using an organic solvent, and the organic solvent is selected from water or alcohol or a combination thereof. The composition comprising a mulberry extract according to claim 1 or 6, wherein the mulberry extract is obtained by a method that does not use an organic solvent, and the method may be selected from supercritical fluid extraction, microwave-assisted extraction, or ultrasonic extraction Any one or more of them. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used as a tonic and/or adaptogen. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used as a cognitive enhancer. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used to reduce the risk of liver disease. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used to reduce the risk of peptic ulcer. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used to reduce the risk of metabolic syndrome. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used to reduce the risk of obesity. The composition comprising a mulberry extract according to claim 1, wherein the composition can be used to reduce the risk of cardiovascular disease. Beverages, food supplements or health products, including the composition according to any one of claims 1 to 15. The food, beverage, milk or food supplement or health product as described in claim 16, wherein the food, beverage, milk or food supplement or health product may be tablets, capsules, effervescent granules or tablets, granules In the form of medicine, powder, gel, jelly, glue, candy, spray, film, patch, cream, ointment, lotion.

Images